Convergent Therapeutics, Inc.
Nicole Schreiber is a Senior Director of Clinical Strategy at Convergent Therapeutics, Inc. since August 2021, bringing extensive experience in clinical research and strategy development. Previously, Nicole served as Associate Director at the Prostate Cancer Clinical Trials Consortium from January 2018 to August 2021, where responsibilities included developing partnerships for multicenter clinical trials and overseeing budget and data analysis. Nicole's earlier roles at Memorial Sloan Kettering Cancer Center included Research Project Manager, Clinical Research Supervisor, and Research Project Coordinator, focusing on blood-based biomarker research within the Genitourinary Oncology service. Additionally, Nicole began a research career as a Laboratory Research Assistant at the University of Maryland College Park, contributing to environmental microbiology studies. Nicole earned a Bachelor of Arts in English Language and Literature from the University of Maryland.
This person is not in any teams
Convergent Therapeutics, Inc.
Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.